Optimistic venture investors frequently speculate regarding how promising firms can win a share of a sizable total addressable market (TAM). However, it can also be applied in the opposite direction. New anti-obesity medications have the power to drastically change public health while removing the need for goods and services from the healthcare, food, and fitness sectors. Consider them to be TUMs or total unaddressable markets.
The first successful diet medications appear to be those created by Novo Nordisk and Eli Lilly. They function by focusing on brain receptors that lessen appetite and make individuals feel fuller for more. They were first created to combat diabetes, but they are also becoming popular for treating obesity.
Patients receiving the soon-to-be-released weight-loss medication from Eli Lilly shed nearly 50 pounds (23 kg) in one research experiment. The advantages for general health could be enormous. Wegovy, a medicine Novo developed to treat obesity, was reported to have a 20% lower incidence of major cardiovascular events, such as heart attacks and strokes, among overweight people without diabetes who had a previous record of heart disease.
Leave a Reply